With 365% stock climb, this Bay Area drug maker has skin in the game
Wall Street is scratching its health-care itch, nearly quadrupling the value of Anacor Pharmaceuticals Inc.'s stock on the hopes of quick regulatory approval and a potential 2017 launch of the company's late-stage eczema treatment.
(Scroll down to see a chart of the rapid rise of Anacor's stock)
Much of the stock boom came this month, after Palo Alto-based Anacor (NASDAQ: ANAC) announced early data from two studies of crisaborole — formerly known as AN-2728 — in people with raised, red, itchy…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Ron Leuty Source Type: news
More News: Eczema | Health | Health Management | Hospital Management | Hospitals | Itchiness | Skin | Study